Related references
Note: Only part of the references are listed.Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
Ambuj Kumar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
被撤回的出版物: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma:: results of a multicenter randomized clinical trial (Retracted article. See vol. 113, pg. 6265, 2009)
Abderrahman Abdelkefi et al.
BLOOD (2008)
Clinically relevant end points and new drug approvals for myeloma
K. C. Anderson et al.
LEUKEMIA (2008)
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
Pieter Sonneveld et al.
HAEMATOLOGICA (2007)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
P Moreau et al.
BLOOD (2002)
Share Paper
